The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer
Abstract Carriers of germline BRCA2 pathogenic sequence variants have elevated aggressive prostate cancer risk and are candidates for precision oncology treatments. We examined whether BRCA2-deficient (BRCA2 d ) prostate tumors have distinct genomic alterations compared with BRCA2-intact (BRCA2 i )...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Nature Portfolio
2022-06-01
|
| Cyfres: | npj Precision Oncology |
| Mynediad Ar-lein: | https://doi.org/10.1038/s41698-022-00284-6 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|